Dosage of Reboxetine Mesylate in details
Oral
Depression
Adult: 4 mg bid, may increase to 10 mg daily after 3-4 wk if necessary. Max: 12 mg daily.
Elderly: 2 mg bid, may increase dose to 6 mg/day after 3 ww if required.
Renal impairment: Initiate with lower doses: 2 mg bid; may increase gradually according to tolerance.
Hepatic impairment: Initiate with lower doses: 2 mg bid; may increase gradually according to tolerance.
Reboxetine Mesylate interactions
In vitro and in vivo studies have shown that Reboxetine Mesylate is not metabolized by CYP-450 2D6. Therefore, no special precautions are necessary for individuals deficient in this enzyme. Likewise, inhibitors of this enzyme eg, fluoxetine and paroxetine, are unlikely to have an effect on Reboxetine Mesylate pharmacokinetics.
In vitro studies have shown that Reboxetine Mesylate does not inhibit the activity of the following CYP-450 isozymes: CYP1A2, CYP2C9, CYP2C19 and CYP2E1. At high concentrations, Reboxetine Mesylate inhibits CYP2D6, but the clinical significance of this observation is unknown. In vitro studies show that Reboxetine Mesylate is a very weak inhibitor of CYP3A4.
In vitro metabolism studies indicate that Reboxetine Mesylate is metabolized by the CYP3A4 isozyme of CYP-450. Therefore, compounds which modulate the activity of this isozyme, would be expected to increase plasma concentrations of Reboxetine Mesylate.
References
- FDA/SPL Indexing Data. "L8S50ZY490: The UNique Ingredient Identifier (UNII) is an alphanumeric substance identifier from the joint FDA/USP Substance Registration System (SRS).". https://www.fda.gov/ForIndustry/Data... (accessed September 17, 2018).
- MeSH. "Adrenergic Uptake Inhibitors". https://www.ncbi.nlm.nih.gov/mesh/68... (accessed September 17, 2018).
- Wikipedia. "2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine: Link to the compound information in Wikipedia.". https://en.wikipedia.org/wiki/Reboxe... (accessed September 17, 2018).
Reviews
The results of a survey conducted on ndrugs.com for Reboxetine Mesylate are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Reboxetine Mesylate. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.User reports
Consumer reported frequency of use
No survey data has been collected yetConsumer reported doses
No survey data has been collected yetConsumer reviews
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
